A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial

William J. Sandborn; Christopher Gasink; Long-Long Gao; Marion Blank; Jewel Johanns; Cynthia Guzzo; Bruce E. Sands; Stephen B. Hanauer; Stephan R. Targan; Paul J. Rutgeerts; Subrata Ghosh; Willem de Villiers; Remo Panaccione; Gordon R. Greenberg; Stefan Schreiber; Simon Lichtiger; Brian G. Feagan

doi:10.1016/s0016-5085(11)60443-5

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial

Gastroenterology ◽

10.1016/s0016-5085(11)60443-5 ◽

2011 ◽

Vol 140 (5) ◽

pp. S-109 ◽

Cited By ~ 17

Author(s):

William J. Sandborn ◽

Christopher Gasink ◽

Long-Long Gao ◽

Marion Blank ◽

Jewel Johanns ◽

...

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Human Monoclonal Antibody ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297850.792702851 ◽

2012 ◽

Author(s):

Gwo-Tzer Ho

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

CDP571, a humanised monoclonal antibody to tumour necrosis factor , for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

Gut ◽

10.1136/gut.2003.035253 ◽

2004 ◽

Vol 53 (10) ◽

pp. 1485-1493 ◽

Cited By ~ 118

Author(s):

W J Sandborn

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Gut ◽

10.1136/gutjnl-2011-301668 ◽

2012 ◽

Vol 61 (12) ◽

pp. 1693-1700 ◽

Cited By ~ 810

Author(s):

Wolfgang Hueber ◽

Bruce E Sands ◽

Steve Lewitzky ◽

Marc Vandemeulebroecke ◽

Walter Reinisch ◽

...

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Mo1213 Efficacy and Safety of NNC0142-0002, a Novel Human Monoclonal Antibody Targeting NKG2D: a Randomized, Double-Blind, Single-Dose Phase 2 Trial in Patients With Crohn's Disease

Gastroenterology ◽

10.1016/s0016-5085(14)62128-4 ◽

2014 ◽

Vol 146 (5) ◽

pp. S-587 ◽

Cited By ~ 1

Author(s):

Matthieu Allez ◽

Robert Petryka ◽

Brett E. Skolnick ◽

Maria A. Wisniewska-Jarosinska

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Single Dose ◽

Crohn's Disease ◽

Human Monoclonal Antibody ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Phase 2 Trial ◽

Antibody Targeting

Download Full-text

Faculty Opinions recommendation of Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297850.793505750 ◽

2015 ◽

Author(s):

Vijay Kuchroo

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

Gastroenterology ◽

10.1016/s0016-5085(08)60317-0 ◽

2008 ◽

Vol 134 (4) ◽

pp. A-67 ◽

Cited By ~ 2

Author(s):

Christien J. van der Woude ◽

Pieter C. Stokkers ◽

Ad A. van Bodegraven ◽

Gert A. Van Assche ◽

Zbigniew Hebzda ◽

...

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Phase I ◽

Dose Escalation ◽

Safety Profile ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297850.793152976 ◽

2012 ◽

Author(s):

Eduard Stange

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease

Gastroenterology ◽

10.1053/j.gastro.2004.05.010 ◽

2004 ◽

Vol 127 (1) ◽

pp. 332 ◽

Cited By ~ 37

Author(s):

Stephen Hanauer ◽

Milan Lukáš ◽

Donald MacIntosh ◽

Paul Rutgeerts ◽

William Sandborn ◽

...

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Tnf Α

Download Full-text

Ornidazole for Prophylaxis of Postoperative Crohn's Disease Recurrence: A Randomized, Double-Blind, Placebo-Controlled Trial

Yearbook of Gastroenterology ◽

10.1016/s0739-5930(08)70327-1 ◽

2006 ◽

Vol 2006 ◽

pp. 117-118

Author(s):

G.R. Lichtenstein

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Disease Recurrence ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OP025. A randomized, double-blind placebo-controlled phase 2a induction study of MEDI2070 (anti-p19 antibody) in patients with active Crohn's disease who have failed anti-TNF antibody therapy

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jju027.025 ◽

2015 ◽

Vol 9 (suppl 1) ◽

pp. S15-S16 ◽

Cited By ~ 7

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Antibody Therapy ◽

Double Blind ◽

Double Blind Placebo ◽

Induction Study

Download Full-text